Research that Identifies
Undiscovered Value in the MicroCap Market



Nephros, Inc.

Nephros, Inc. Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC

Report Link: Updated Research Report (Dated 11/12/2019)

Symbol: NEPH
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: $15.50
Time Horizon: 12 Months
Rating Established: April 24, 2019
Price When Established: $4.50
Most Recent Report: November 12, 2019
Price When Issued: $8.55


What's New

Nephros Launches its PluraPath Water Pathogen Detection System

On January 9, 2020, , Nephros, Inc. announced it formally launched its PluraPath Water Pathogen Detection System. PluraPath is designed to provide actionable data for infection control teams on up to 15 different pathogens from a single water sample in approximately one hour.

NEPH will initially work with its strategic distributors to provide capability demonstrations to medical facilities across the country.


Nephros Announces Preliminary Sales for 4Q19 and FY19

On January 6, 2020, , Nephros, Inc. announced preliminary sales for the three and twelve months ended December 31, 2019.

Nephros expects to report total sales of approximately $3.2 million or a 99% increase from 4Q18. Full year 2019 sales should approximate $10.3 million.

We project 4Q19 and 2019 sales of $2.5 million and $9.7 million, respectively


Company Description

Nephros Inc., headquartered in South Orange, New Jersey, is a water purification company that develops and sells high performance filters and ultrafilters (filters with pore size below 0.01 microns) primarily to hospitals for the prevention of infection from waterborne pathogens and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrates. An acquisition in December 2018 expanded NEPH’s commercial market footprint to include the food service and hospitality industries. The company’s 62.5% owned subsidiary, Specialty Renal Products is a development stage company focused on improving therapies for patients with renal disease.


Company Reports

Updated Research Note (Dated 11/12/2019)

Updated Research Note (Dated 10/16/2019)

Updated Research Report (Dated 08/14/2019)

Updated Research Report (Dated 05/14/2019)

Initial Research Report (Dated 04/24/2019)


Disclaimer

Please view our current disclosure and disclaimer on our most recent research report.